Fluorescence lifetime is an intrinsic parameter describing the fluorescence process. Changes in the fluorophore's physicochemical environment can lead to changes in the fluorescence lifetime. When used as the readout in biological assays, it is thought to deliver superior results to conventional optical readouts. Hence it has the potential to replace readout technologies currently established in drug discovery such as absorption, luminescence or fluorescence intensity. Here we report the development of an activity assay for human kallikrein 7, a serine protease involved in skin diseases. As a probe, we have selected a blue-fluorescent acridone dye, featuring a remarkably long lifetime that can be quenched by either of the 2 natural amino acids, tyrosine and tryptophan. Incorporating this probe and 1 of the quenching amino acids on either side of the scissile bond of the substrate peptide enables us to monitor the enzymatic activity by quantifying the increase in the fluorescence lifetime signal. A systematic investigation of substrate structures has led to a homogenous, microplate-based, compound profiling assay that yields inhibitory constants down into the single-digit nanomolar range. This type of assay has now been added to our standard portfolio of screening techniques, and is routinely used for compound profiling. (Journal of Biomolecular
INTRODUCTION
M ANY DRUG DISCOVERY GROUPS HAVE BUILT UP LARGE COLLECTIONS of chemical compounds over many years of their work in medicinal chemistry. Such compounds are used as potential starting points in drug discovery based on screening campaigns on a particular target protein. Campaigns often employ biochemical assays based on dye-labeled substrates that the target protein can cleave, phosphorylate, or alter in some other way as an indicator for the enzymatic activity. Fluorescence intensity-based techniques have long been chosen for their ability to detect relatively low concentrations of labeled substrates and small changes therein. [1] [2] [3] [4] [5] However, there are many artifacts associated with the fluorescence intensity signal, stemming from compounds in the libraries of low molecular weight compounds, for instance, light scattering, inner filter effect, or autofluorescence. Fluorescence lifetime has been proposed as a tool in the discovery process of new drug candidates. 6 The fluorescence lifetime is an intrinsic property of each individual label and should, therefore, provide for a signal that can be discriminated against many experimental artifacts. 7, 8 Despite its inherent advantages, fluorescence lifetime readouts have not yet been fully adopted to routine use in pharmaceutical research. The reasons for this may include a lack of appropriate instruments and suitable substrates, and a deficiency in the understanding of the link between the biological reaction under scrutiny and the fluorescence lifetime signal. In our opinion, assays in biomedical research need to fulfill at least 4 basic criteria: i) the signal can be measured; ii) a change in the signal can be measured, that is, the signal change is much larger than the experimental noise; iii) the signal change correlates with the (bio-)chemical effect to be monitored; and iv) no further parameters influence the signal change. With fluorescence lifetime there are a number of environmental parameters influencing the signal; controlling 1 parameter and fixing all others seemed impossible. Our earlier (failed) attempts at developing a generic lifetime-based assay format indicated that the main issue here was controlling the change of the lifetime signal (unpublished data). To overcome this problem we decided to introduce a specific interaction between a label and a quencher.
The first critical issue in all systems tested was the unfavorable ratio of 2 quenching modes: on the one hand, the desirable dynamic or collisional quenching that influences the lifetime of the excited state, and on the other hand, a static mode, that changes the total intensity of the sample without having a usable effect on the lifetime. Usually both modes are present; "unfavorable" in the above statement then means that a large proportion of the labels is rendered invisible by being statically quenched. It is then difficult or even impossible to determine the lifetime of the remaining proportion of dynamically quenched labels (requirement i).
Second, the fluorescence lifetime in the nonquenched state must be long enough to allow for a significant reduction by the quenching process, to fulfill requirement ii. Many organic fluorophores exhibit (in aerated aqueous solution) a lifetime of between 1 ns and 7 ns. 9 With experimental errors in the order of 0.1 ns, a signal change of about 4 ns seems desirable (for details see the Results section).
Third, if uncontrollable parameters were to affect the lifetime under assay conditions, then the signal change could not unambiguously be attributed to the reaction to be monitored.
Once an assay signal fulfills these basic requirements, the implementation and application in the drug discovery environment adds further conditions, for example, robustness against small chemical and procedural variations, commercial availability of measurement equipment and chemicals, total costs per measurement point, adaptability to miniaturization, and measurement times acceptable to fully automated screening procedures.
For this report, all lifetime measurements were performed on a commercially available microplate reader, the TECAN Ultra Evolution. The measurement technique works in the time domain; that is, the nanosecond fluorescence intensity decay is recorded after short excitation pulses. The decay curves are collected from single photon events, a technique known as timecorrelated single photon counting (TCSPC). 10 A subsequent curve fit to the intensity decay curve assuming a suitable decay model yields the lifetime values. To achieve the abovementioned experimental errors of below 0.1 ns in the fitted lifetime value, a measurement time per sample of 1 s was necessary, translating into approximately 8 min per 384-well plate inclusive of the data fitting time. For our medium-throughput compound profiling application, this processing time is acceptably short, whereas for high-throughput screening (HTS) a significant reduction would be desirable.
To demonstrate the potential of this new assay principle, human kallikrein 7 (hK7, KLK7, SCCE, stratum corneum chymotryptic enzyme, UniProt accession P49862), an S1 family protease displaying chymotrypsin-like activity, was assayed as a pilot case. Human kallikrein 7 is expressed mainly in the skin and is secreted to the stratum corneum extracellular space as an inactive zymogen where it is activated by kallikrein 5. 11, 12 In the active form, kallikrein 7 cleaves corneodesmosin (CDSN) and desmocollin 1 (DSC1). Both CDSN and DSC1 are corneodesmosomes providing the strong intercorneocyte cohesion in the stratum corneum. Degradation of the intercellular adhesive structures by proteolytic cleavage has been shown to be a key event for desquamation. 13, 14 Proteolytic hyperactivity in the stratum corneum is hypothesized to result first in an impaired skin barrier function leading to dermatological diseases, for example, atopic dermatitis. The extracellular proteolysis of the desmosomes takes place in the outer layer of the skin.
In this article we report, to the best of our knowledge, the first fluorescence lifetime-based biochemical assay that is being routinely used in an industrial setting. Here, we lay out the principles of the assay development; the presentation of screening results lies beyond the scope of this article and will thus be the subject of a future publication.
Our chosen fluorescent marker is unusual in so far as it exhibits a relatively long lifetime of about 14 ns in its nonquenched state. 15 It is dynamically quenched by the natural amino acids tyrosine and tryptophan. We show how the lifetime change can be engineered by selecting the correct quencher and adjusting the distance between label and quencher. Finally, we detail the development, application and validation of an in vitro protease assay for kallikrein 7 in a format that can be routinely used for a wide variety of proteases. The 2 main advantages compared with fluorescence intensity-based assays employing UV-excitable fluorophores are i) the significantly reduced interference by background fluorescence, and ii) that this novel assay format might be of broader use for compound profiling of other proteases, endopeptidases and exopeptidases. Modifications of that principle might be applicable for other target families such as kinases, phosphatases, hydrolases, and many more. The fluorescence lifetime readout technology will have a strong positive impact on the quality and efficiency of compound testing in biochemical assays throughout the whole drug discovery process.
MATERIALS AND METHODS

The fluorescent-labeled peptides, buffer conditions, and enzyme inhibitor
All fluorescently labeled substrates were purchased from Biosyntan (Berlin, Germany). The substrates were acetylated at the N-terminus and amidated at the C-terminus, respectively. They were delivered as dry powders. The purity of the individual preparation was stated by the supplier to be ≥95% as determined by high-performance liquid chromatography (HPLC). The powders were dissolved in dry DMSO and kept as 5 mM stock solutions at -20°C. All other chemicals were of analytical grade.
The lifetime probe PT14 (PureTime  14; 6-(9-oxo-9H-acridin-10-yl)-hexanoate) was purchased from AssayMetrics (Cardiff, UK). The concentrations of the PT14-containing substrate solutions were determined by absorption measurements using the molar extinction coefficient of ε = 7580 M -1 cm -1 (at 394 nm in aqueous solution) for PT14.
The pH at the skin surface is weakly acidic and therefore the assay presented here was adjusted to run at pH 5.6. 12, 13 Enzymatic reactions were conducted in "assay buffer," comprising 50 mM sodium citrate buffer at pH 5.6, containing 150 mM sodium chloride (NaCl) and 0.05 % (wt/vol) CHAPS (3-((3-cholamidopropyl)-dimethylammonio)-propanesulfonate).
All protein and peptide containing solutions were handled in "Maxymum Recovery" tubes (Axygen Scientific Inc., Union City, CA). The compound solutions as well as the enzyme and the substrate solutions were transferred to 384-well plates (Black Microtiter 384 Plate, round well, catalog number 95040020; Thermo Electron Oy, Finland) by means of a CyBi-Well 96-channel pipettor (CyBio AG, Jena, Germany).
The test compound 2-(2-fluoro-phenyl)-5,6,7,8-tertrahydorbenzol [4, 5] thieno[2,3-d] [1, 3] oxazin-4-one was purchased form InterBioScreen (Moscow, Russia). It was dissolved in 90% (v/v) DMSO/water and kept at a stock concentration of 10 mM at 4°C.
Cloning, expression, and purification of human kallikrein 7
The coding sequence of human pro-kallikrein 7 was amplified by PCR and cloned into a modified pET24 (Novagen; EMD Chemicals, Gibbstown, NJ) expression plasmid that allows expression of pro-kallikrein 7 N-terminally fused to a His-tag and a PreScission cleavage site. To facilitate activation of the enzyme an enterokinase cleavage site was introduced additionally by sitedirected mutagenesis between the propeptide and the mature N-terminus of human kallikrein 7. The final expression plasmid pET24-His-ProKLK7-EK-KLK7 (amino acids 37-253) was introduced in Escherichia coli strain BL21(DE3) and recombinant human kallikrein 7 was expressed in the form of inclusion bodies.
After preparation and purification using an anion exchange chromatography, the inclusion bodies were dissolved in 50 mM Tris/HCl pH 8.0 buffer containing 6 M urea (Fluka; Sigma-Aldrich Chemie, Buchs, Switzerland) and 50 mM dithiothreitol (DTT) and purified by anion exchange chromatography (Q-sepharose; GE Healthcare, Munich, Germany). Refolding was done by rapid dilution to a final concentration of 50 µg/ml in 50 mM Tris/HCl pH 8.0 buffer (cooled to 10°C) containing 2 M urea, 500 mM NaCl, 10 mM CaCl 2 , 100 mM NH 4 Cl, 1 mM ethylene diamine tetraacetic acid (EDTA), 1.25 mM glutathione, and 0.5 mM oxidized form of glutathione. Subsequently, the sample was dialyzed against 10 mM Tris pH 8.0 buffer and purified by anion exchange chromatography (Qsepharose). The concentrated pro-kallikrein 7 fractions were activated by adding enterokinase (1:100) for 24 h at 8°C and purified by size exclusion chromatography (Superdex 75; GE Healthcare) using 50 mM Tris buffer, 100 mM NaCl, pH 8.
The amount of active human kallikrein 7 was determined by an active site titration with a highly potent, proprietary inhibitor, using the EDANS/DABCYL-labeled peptide in a fluorescence intensity-based assay.
Instrumentation for fluorescence measurements
Fluorescence measurements were conducted on an Ultra Evolution fluorescence lifetime reader (TECAN, Maennedorf, Switzerland).
For intensity measurements, the instrument was equipped with bandpass filters, 350 nm (20 nm bandwidth) and 500 nm (25 nm bandwidth) for fluorescence excitation and emission acquisition, respectively. To increase the signal-to-background ratio, a dichroic mirror with a cutoff wavelength at 410 nm was used. The fluorescence intensity of each well was averaged over 3 flashes per measurement.
For lifetime measurements, the excitation light source was a semiconductor laser at 405 nm, producing picosecond light pulses with a selected repetition frequency of 10 MHz. The emission was collected through a 450-nm bandpass filter with 25-nm bandwidth. The measurement time per well was set to 1 s, yielding approximately 1000 counts in the peak channel. The initial curve fitting was done automatically by the instrument control software. The parameters used as assay readout are the monoexponential lifetimes.
Calculation of the product concentration from measured fluorescence lifetime data
Assuming monoexponential intensity decays for the parent (index: par) and cleaved (index: inf) substrates, a mixed sample will generally produce a biexponential decay. The average fluorescence lifetime,
as calculated from the amplitudes α and lifetimes τ of the biexponential decay curve,
can be transformed into the concentration of the cleavage product, [P], by the expression
with the ratio of the steady-state intensities (I inf /I par ) of PT14 in the cleavage product and in the parent substrate, and where [S o ] is the initial substrate concentration. 16 In practice it is often more appropriate to fit the decay curves of mixed samples with a monoexponential instead of a biexponential model, thus approximating the average lifetime.
Fluorescence Lifetime-Based Protease Assay
Determination of kinetic constants K M and k cat for the fluorescent substrate under initial velocity conditions
The Michaelis constant, K M , was obtained from measurements conducted at a constant enzyme concentration of 25 nM and different substrate concentrations up to 75 µM. Under these conditions the substrate concentration, [S], is significantly higher than the enzyme concentration; as long as the substrate consumption is below 20%, the initial enzymatic velocity, v, can be approximated by the Henri-Michaelis-Menten equation
where v max is the maximal velocity at saturating substrate concentrations. Equation 4 can be applied to the curve obtained by plotting the measured enzyme velocities versus the corresponding substrate concentration leading to the values for K M and v max by a nonlinear regression fit.
The k cat value is then defined as
where [E o ] is the employed enzyme concentration. For the determination of the initial rate constants, the experimental data were fitted using the nonlinear regression program Origin 7.5SR6 (OriginLab Corporation, Northampton, MA).
Determination of IC 50 values
For the determination of IC 50 values, the assay was performed at room temperature in 384-well plates with a total assay volume of 30 µl per well. The test compound was dissolved in 90% (v/v) DMSO/water and diluted in water containing 0.05% (wt/vol) CHAPS to 3 times the desired assay concentration. For the assay, 10 µl of water/CHAPS (± test compound) were added per well, followed by the addition of 10 µl of protease solution (diluted with 1.5× assay buffer). The final assay concentrations of human kallikrein 7 were 0.2 nM in the intensity assay and 2.5 nM in the lifetime assay. After 1 h of preincubation at room temperature, the reaction was started by the addition of 10 µl of substrate solution (in 1.5× assay buffer, final assay concentrations were 2 µM in the intensity and 0.6 µM in the lifetime assay). After the addition of the substrate solution, the final DMSO concentration in the assay was 0.9% (v/v). The effect of the compound on the enzymatic activity was obtained from the linear part of the progression curves and determined after 1 h (t = 60 min). The IC 50 value was calculated from the plot of percentage of inhibition vs. inhibitor concentration by a logistics fit according to y = A2 + (A1 -A2)/(1 + (x/IC 50 )^p) (6) where y is the %-inhibition at the inhibitor concentration, x. A1 is the lowest inhibition value, that is, 0%, and A2 the maximum inhibition value, that is, 100%. The exponent, p, is the Hill coef-ficient. The curve fitting was conducted with the nonlinear regression routine of the analysis software Origin 7.5SR6 (OriginLab Corporation).
RESULTS
Identification and optimization of the substrate sequence
The design of the initial substrate sequence was based on results gathered by testing a selection of substrates all containing aromatic amino acids phenylalanine, tyrosine, or tryptophan, which are necessary for a primary cleavage site for the chymotrypsin-like protease human kallikrein 7. In these tests, the substrate usually employed for monitoring cathepsin D and E activity (reference FI-1 in Table 1 ) showed the highest turnover. However, product inhibition was observed after 50% consumption of the substrate (data not shown). The elimination of 1 phenylalanine in the sequence resulted in similar turnover rates, but a significantly reduced level of product inhibition. This optimized substrate (FI-2) was selected for in-house profiling on kallikrein 7 using a fluorescence intensity-based assay.
We took the substrate FI-2 as a starting point for the development of a fluorescence lifetime assay. The EDANS carrying amino acid lysine was replaced by tyrosine and the DABCYL was exchanged for PT14. The enzymatic cleavage of this substrate yielded a lifetime difference of 1.8 ns between the parent substrate and the cleaved product. Compound profiling under initial velocity conditions limits the maximum substrate consumption to the range of 15% to 20% of the initial substrate concentration, which translates to an assay window of only 0.3 ns. Compared with the typical experimental error of 0.1 ns this signal change is not sufficient to yield a functional assay.
The assay readout was then optimized stepwise by varying the type, number, and position of the quencher. The lifetime change of the PT14-labeled substrate upon enzymatic cleavage increased from 1.8 to 5.5 ns ( Table 1 ). The optimization comprised adding a second tyrosine to increase the number of quenchers, then the tyrosine was replaced by tryptophan as a more efficient quencher, a second tryptophan was added to increase the local concentration of quenchers, and finally the quencher was moved closer to the probe by replacing phenylalanine in P1 (according to the nomenclature of Schechter and Berger) with tryptophan. 17 Representatively, Figure 1 shows the fluorescence intensity decay curves of the fluorophore PT14 in the parent substrate FLT-5 (lower curve; blue) and in the corresponding cleaved product (upper curve; red). The solid lines represent the curve fit assuming a monoexponential decay model; the corresponding fit residuals are displayed in the lower panel.
To show the correlation between the lifetime signal and the biological effect to be monitored, we synthesized a shortened peptide equivalent to the enzymatically cleaved peptide carrying the fluorescent dye (FLT-5inf, Table 1 ). The full-length peptide and this short peptide were mixed at various molar ratios, and the respective fluorescence lifetimes determined. The resulting plot (Fig. 2) follows equation 3. Up to a molar fraction of 15% short peptide (i.e., the product) the correlation is approximately linear. Proportionally the largest lifetime change occurs for low fractions of product; in other words, the lifetime signal is highly sensitive in this range of the enzymatic reaction. In subsequent experiments we use an assay window of 8.4 to 9.7 ns, corresponding to well below 20% product formation.
With this finding the basic assay signal requirements stated in the Introduction section are therefore fulfilled.
Assay development for human kallikrein 7
The kinetic constants of the proteolysis of the substrate FLT-5 by kallikrein 7 were determined from the time courses of product formation under initial velocity conditions according to equation 4. While the enzyme concentration was kept at 25 nM, the substrate concentrations were 0, 0.4, 0.7, 1.9, 3.7, 7.5, 18.7, 37.3, and 74.6 µM. To calculate the initial velocity for each substrate concentration tested, the lifetime values were first transformed into product concentrations (equation 3), with τ par = 8.4 ns, τ inf = 13.9 ns, and I inf / I par = 2.6. The slopes of the kinetic traces were subsequently plotted against the initial substrate concentration, see For the EDANS/DABCYL-labeled substrate with an analogue peptide sequence, initially used as the template for the development of the fluorescence lifetime substrate, K M and k cat /K M values of 5.9 µM and 1.7 ⋅ 10 5 M -1 s -1 , respectively, have been determined under identical assay conditions (data not shown). According to these data, the fluorescence lifetime substrate is roughly 17 times less efficiently processed by kallikrein 7 than the fluorescence intensity (FI) substrate used as the template.
To optimize the assay further, the reaction was conducted with different enzyme concentrations at constant substrate concentration. The enzyme reaction was found to be linear up to 1 h for enzyme concentrations up to at least 0.8 nM ( Fig. 4A  and B) . However, nominally 2.5 nM kallikrein 7 was required in assays utilizing automated liquid handling because of activity losses. Such an increase in the required enzyme concentration is often observed when assays are adapted to automated liquid handling stations and should not give rise to any concern.
To investigate the tolerance of the assay toward DMSO, a solvent typically used to dissolve test compounds, the DMSO concentration was varied between 0% and 2% (v/v) at otherwise constant conditions. The catalytic activity of the protease decreased with increasing DMSO concentrations (not shown). At 1% (v/v) DMSO, the proteolytic activity of kallikrein 7 is reduced by 14%, at 2% (v/v) DMSO by 22% in comparison with the DMSO-free conditions. Inasmuch as the final DMSO concentration for routine compound testing remains below 1% (v/v), where only little impact on protease activity was observed, the influence of DMSO on the determination of IC 50 values can be neglected.
Finally, we compared results of inhibition experiments obtained using the novel lifetime-based assay format with those obtained with a previously established fluorescence intensitybased assay. A known inhibitor for S1 serine proteases, 2-(2fluoro-phenyl)-5,6,7,8-tertrahydro-benzol [4, 5] 3]oxazin-4-one, was tested in the 2 different assay formats. Figure 5 shows the dose-response curves. Both assay types yield almost identical IC 50 values for the inhibitor of 70 nM. This commercially available inhibitor is a member of the thieno[2,3-d] [1, 3] oxazin-4-one series. Members of this series of compounds have been described previously as inhibitors of the S1 serine protease human leukocyte elastase. 18, 19 Inhibitors from this structural class bind covalently to the enzyme (acylenzyme inhibitors) and are irreversible with respect to their structure after deacylation. Within their class, the 3,1-benzoxazin-4-ones, thieno[2,3-d] [1, 3] oxazin-4-ones were optimized for a low deacylation rate resulting in enhanced stability of the thiophene-derived acyl-enzymes and a slower inhibitor consumption. The acylation of human kallikrein 7 by 2-(2fluoro-phenyl)-5,6,7,8-tertrahydro-benzol [4, 5] thieno[2,3-d] [1, 3] oxazin-4-one is fast with a rate constant of k on = 2.5 ⋅ 10 3 M -1 s -1 , whereas the acyl-enzyme intermediates are stable with a half-life of 40 min under these assay conditions (data not shown). Although the binding of irreversible inhibitors is characterized by second-order rate constants, the kinetic properties of the chosen inhibitor allow the determination of an equilibrium IC 50 value with the presented assay procedure for the purpose of comparing assay types. The major advantage of the novel assay format over the previously used standard fluorescence intensity assays employing EDANS/DABCYL as fluorophore/quencher pair can be illustrated by the direct comparison of representative dose-response curves obtained for a proprietary inhibitor carrying a molecular moiety that is fluorescent when excited at 350 nm and therefore interferes with the intensity readout (cf. Fig. 6A and B) . In the case of the FI assay, the 4 data points obtained for the compound concentrations above 0.3 µM were excluded manually prior to the curve fitting to yield IC 50 data. For the fluorescence lifetimebased assay, no interference was observed and the curve fit could be conducted automatically without any data manipulation. For the example shown here, the data sets from both assay formats yield similar IC 50 values in the range of 4 to 6 nM.
DISCUSSION
In this publication we have described the development of a nanosecond fluorescence lifetime-based compound profiling assay, utilizing an acridone derivative (PureTime  14, PT14) probe. We have incorporated this probe into a novel substrate Ac-E.F.K.P.I.L.W.R.L.G.C(PT14).E-NH 2 , which is the first reported endopeptidase substrate for assaying the serine protease human kallikrein 7 in vitro.
We have optimized the substrate with respect to the applied detection technique by testing a small library of monolabeled peptides. Starting with a peptidic substrate previously known to work in a fluorescence intensity-based assay, we replaced the existing probe with PT14, and varied the type, number, and position of quenchers. Enzymatic cleavage of the tryptophanarginine bond resulted in a 5.5-ns increase of the probe's fluorescence lifetime. We then used this substrate to develop a biochemical assay for the serine protease human kallikrein 7. A value of 1 ⋅ 10 4 M -1 s -1 was determined for the second order rate constant, k cat /K M , that characterizes the enzymatic reaction with the PT14-labeled substrate. Compared with the value obtained for the hydrolysis of the EDANS/DABCYL-labeled substrate, a 17-fold difference in favor of the hydrolysis of the fluorescence intensity substrate was observed. This finding most likely reflects the enzyme's preference for amino acids with smaller side chains compared with tryptophan in the P1 position of the substrate sequence. 20 This P1 phenylalanine was replaced by a tryptophan for the optimization of the fluorescence lifetime signal. A k cat /K M value in the range of 1 · 10 4 M -1 s -1 , together with a substrate concentration in the low micromolar range, still only requires an enzyme concentration in the low nanomolar range to obtain assay linearity for more than 1 h. In the present case the assay was run with a substrate concentration significantly below the K M value and an enzyme concentration of 2.5 nM. Because for competitive reversible inhibitors the lower limit of the quantifiable IC 50 value equals half the utilized enzyme concentration, we can determine IC 50 values down to the single-digit nanomolar range.
The known S1 protease inhibitor 2-(2-fluoro-phenyl)-5,6,7,8-tertrahydro-benzol [4, 5] thieno [2,3-d] [1, 3] oxazin-4-one was used to test whether the novel assay format could be used in compound profiling. Inhibition experiments with both, the intensity-based and the lifetime-based format, yielded identical results. Both assays were conducted with substrate concentrations below the corresponding K M values, and therefore the obtained result also reflects that K i values determined with both assays are identical within the limits of the experimental error.
Finally, we assessed assay interference by testing compounds showing autofluorescence in a variety of standard intensitybased endopeptidase assays employing UV-excitable probes. Data obtained with these assays consequently cannot be evaluated. To overcome this issue, a shift to longer wavelength probe/quencher pairs would be desirable. Incidentally, the implementation often fails because of technical challenges during substrate synthesis, that is, the dual-labeling of a peptide.
Our novel fluorescence lifetime assay combines 3 advantages over the previously used standard assays for endopeptidases. Substrate synthesis requires only a single, small, and water-soluble label. The excitation wavelength of this probe of 405 nm compares favorably with the 350 nm of EDANS, thus reducing compound excitation. Compared with fluorescence intensity, the fluorescence lifetime being an intrinsic readout parameter is robust against interference arising from signal extinction by absorption or light scattering by particles.
As an example we have recorded IC 50 curves in both assay formats for an autofluorescent compound. Although the standard intensity data required manual data manipulation, the lifetime data were free from any interference.
Preliminary data (not shown) suggest that even this relatively small red-shift of 55 nm will reduce the proportion of autofluorescent compounds significantly.
In conclusion, we have described a route to develop fluorescence lifetime-based in vitro assays for endopeptidases. The predictability of the signal generation by introducing a probequencher interaction, the control of the dynamic range, and the robustness of the assay in routine screening lay the foundation The profiling data, that is, the IC 50 value of 6 nM and the Hill coefficient of 0.9, could only be obtained after excluding the 4 data points for compound concentrations above 0.3 µM from the curve fit (excluded data are marked with brackets; the point at 30 µM and -128% inhibition is not shown). (B) Result obtained with the novel fluorescence lifetime-based assay. The profiling data, that is, an IC 50 value of 4 nM and a Hill coefficient of 0.9, was obtained without any manipulation on the data.
